Hepatocellular Carcinoma

Stopping liver cancer in its tracks

A University of Tokyo research group has discovered that AIM (Apoptosis Inhibitor of Macrophage), a protein that plays a preventive role in obesity progression, can also prevent tumor development in mice ...

Oct 02, 2014
popularity 5 / 5 (3) | comments 0

New mouse model points to therapy for liver disease

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which ...

Aug 18, 2014
popularity not rated yet | comments 0

Hepatocellular carcinoma (HCC, also called malignant hepatoma) is the most common type of liver cancer. Most cases of HCC are secondary to either a viral hepatitide infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis).

Compared to other cancers, HCC is quite a rare tumor in the United States. In countries where hepatitis is not endemic, most malignant cancers in the liver are not primary HCC but metastasis (spread) of cancer from elsewhere in the body, e.g., the colon. Treatment options of HCC and prognosis are dependent on many factors but especially on tumor size and staging. Tumor grade is also important. High-grade tumors will have a poor prognosis, while low-grade tumors may go unnoticed for many years, as is the case in many other organs, such as the breast, where a ductal carcinoma in situ (or a lobular carcinoma in situ) may be present without any clinical signs and without correlate on routine imaging tests, although in some occasions it may be detected on more specialized imaging studies like MR mammography.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Some people may be pre-wired to be bilingual

(HealthDay)—Some people's brains seem pre-wired to acquire a second language, new research suggests. But anyone who tries to move beyond their mother tongue will likely gain a brain boost, the small study ...

Ebola vaccine promising in first human trials

Researchers say they are one step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

Team finds an off switch for pain

In research published in the medical journal Brain, Saint Louis University researcher Daniela Salvemini, Ph.D. and colleagues within SLU, the National Institutes of Health (NIH) and other academic institutions have d ...